Moving Toward True Personalized Therapy for Patients With Advanced NSCLC
  • CME

Review expert commentary on current best practices for molecular testing and personalizing therapy for patients with advanced NSCLC.
Rathi Pillai, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.20 MB
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: December 19, 2018 Expiration: December 18, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess the appropriate molecular markers to guide clinical decisions for patients with advanced-stage NSCLC
  • Plan individualized treatment strategies based on histology as well as patient age/fitness, comorbidities, and preferences
  • Apply the available data, treatment guidelines, and expert recommendations to select therapy for NSCLC positive for therapeutically-actionable biomarkers

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Rathi Pillai, MD

Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Rathi Pillai, MD, has disclosed that she has received consulting fees from AstraZeneca and funds for research support from Bristol-Myers Squibb.

Staff

Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for medical oncologists, pathologists, pulmonologists, and other healthcare providers who care for patients with non-small-cell lung cancer.

Goal

The goal of this activity is to improve participants’ performance at assessing and then using genomic aberrations to guide treatment choices for patients with NSCLC.

Physician Continuing Medical Education

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 19, 2018, through December 18, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

In this slideset, Val R. Adams, PharmD, FCCP, BCOP, reviews the landscape of EGFR mutations in advanced NSCLC and the pharmacology of EGFR TKIs used in this setting.

Val R. Adams, PharmD, FCCP, BCOP Released: March 25, 2019

In this slideset, Philip Schweiterman, PharmD, MHA, provides pharmacy perspectives in the delivery of care to patients with EGFR-mutated NSCLC.

Philip Schwieterman, PharmD, MHA Released: March 25, 2019

In this slideset, Matthew Gubens, MD, MS, reviews the latest first-line and second-line clinical data in the setting of EGFR mutation–positive NSCLC.

Matthew Gubens, MD, MS Released: March 25, 2019

In this CCO commentary, Farhad Ravandi, MD, discusses the clinical relevance of newly approved drugs and promising investigational agents for acute myeloid leukemia (AML)

Farhad Ravandi, MD Released: March 22, 2019

Acknowledgements

Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Genentech BioOncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?